[CAS NO. 1952272-74-0] Bemarituzumab

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1952272-74-0]

Catalog

HY-P99010

Brand

MCE

CAS

1952272-74-0

DESCRIPTION [1952272-74-0]

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Bemarituzumab]

For research use only. We do not sell to patients.

Summary

Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research ^[1] .

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03694522	Five Prime Therapeutics, Inc.\|Zai Lab (Shanghai) Co., Ltd.	Gastric Cancer	September 14, 2018	Phase 2
NCT05322577	Amgen	Gastric Cancer\|Gastroesophageal Junction Cancer	May 17, 2022	Phase 1
NCT05325866	Amgen	Solid Tumors	September 23, 2022	Phase 1
NCT05111626	Amgen	Gastric Cancer\|Gastroesophageal Junction Adenocarcinoma	March 14, 2022	Phase 3
NCT02213289	University of Chicago\|AbbVie	Adenocarcinoma	January 20, 2015	Phase 2
NCT05052801	Amgen	Gastric Cancer\|Gastroesophageal Junction Adenocarcinoma	March 7, 2022	Phase 3
NCT05267470	Amgen	Squamous-Cell Non-Small-Cell Lung Cancer	March 29, 2022	Phase 1

Appearance

Liquid

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Daniel Vt Catenacci, et al. Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Future Oncol. 2019 Jun;15(18):2073-2082.